Tag:

Liquidia Technologies

Latest Headlines

Latest Headlines

Novel glaucoma drug delivery platform described at ARVO conference

Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL. 

Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia

Liquidia Technologies launched a new company this week with $25 million in Series A funding aimed at developing an extended-release glaucoma treatment that could last for several months after one injection.

Liquidia spins out new biotech with $25M A round

Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $25 million in venture backing from some high-profile investors. 

Liquidia touts promise of next-gen respiratory delivery

Liquidia Technologies' PRINT platform is a particle-engineering technology that has performed well in two recent studies.

Liquidia CEO: Nanotech will outpace biotech

Neal Fowler said a huge market is waiting for nanotech companies; it's just a matter of harnessing the field's potential into practical uses.

With Gates Foundation backing, Liquidia advances novel flu vaccine

Cost is a huge issue in the vaccine industry, especially as companies turn their focus on the developing world. While some groups have looked toward DNA vaccines, virus-like particles (VLPs) and

Gates steps in to vaccine VC with $10M investment

The Bill and Melinda Gates Foundation, long a staunch supporter of vaccines for children, is putting its money where its mouth is with a $10 million investment in Liquidia Technologies. Xconomy notes

Gates Foundation turns biotech investor in $10M Liquidia deal

Liquidia Technologies is getting a $10 million boost from the Bill & Melinda Gates Foundation to support its work on next-gen vaccines. Only this time the charitable foundation is taking an

PATH to use Liquidia particle technology for malaria

The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps

New material for programmable drug-eluting stents

Chemical & Engineering News has reported on research out of North Carolina into a new class of bioabsorbable materials that can be precisely programmed to degrade by hydrolysis in hours, days,